- Home
- XP vs BBIO Comparison
XP vs BBIO Comparison
Compare XP & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XP
- BBIO
- Stock Information
- Founded
- XP 2001
- BBIO 2015
- Country
- XP Cayman Islands
- BBIO United States
- Employees
- XP N/A
- BBIO N/A
- Industry
- XP Investment Bankers/Brokers/Service
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- XP Finance
- BBIO Health Care
- Exchange
- XP Nasdaq
- BBIO Nasdaq
- Market Cap
- XP 9.1B
- BBIO 9.4B
- IPO Year
- XP 2019
- BBIO 2019
- Fundamental
- Price
- XP $17.34
- BBIO $52.86
- Analyst Decision
- XP Strong Buy
- BBIO Strong Buy
- Analyst Count
- XP 6
- BBIO 16
- Target Price
- XP $23.67
- BBIO $64.44
- AVG Volume (30 Days)
- XP 7.2M
- BBIO 2.1M
- Earning Date
- XP 11-18-2025
- BBIO 11-11-2025
- Dividend Yield
- XP 7.96%
- BBIO N/A
- EPS Growth
- XP 18.07
- BBIO N/A
- EPS
- XP 1.67
- BBIO N/A
- Revenue
- XP $3,085,301,717.00
- BBIO $235,812,000.00
- Revenue This Year
- XP $18.43
- BBIO $115.97
- Revenue Next Year
- XP $13.18
- BBIO $65.50
- P/E Ratio
- XP $10.37
- BBIO N/A
- Revenue Growth
- XP 6.65
- BBIO 7.62
- 52 Week Low
- XP $10.82
- BBIO $21.72
- 52 Week High
- XP $20.64
- BBIO $54.60
- Technical
- Relative Strength Index (RSI)
- XP 37.01
- BBIO 56.31
- Support Level
- XP $18.47
- BBIO $51.85
- Resistance Level
- XP $19.21
- BBIO $53.81
- Average True Range (ATR)
- XP 0.63
- BBIO 1.62
- MACD
- XP -0.27
- BBIO 0.03
- Stochastic Oscillator
- XP 5.49
- BBIO 79.38
About XP XP Inc.
XP Inc is a Cayman Island-based technology-driven financial services platform. It is a provider of low-fee financial products and services in Brazil. The company evaluates its business through a single segment such as monitoring operations, making decisions on fund allocation, and evaluating the performance. It generates revenue through the Brokerage commission.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.